Pharmaceutical & Drug Policy
Comments on Medicare Drug Price Negotiation Program’s Section 30.2 and Part B high spend drugs
On April 20, the Engelberg Center convened an expert workshop to discuss prescribing information for health care professionals.
This workshop brought together a diverse set of stakeholders who discussed the following issues:
- How the prescribing information (PI) is currently accessed and utilized;
- If the current PI format is meeting the needs of prescribers and other health care professionals and if all PIs should be standardized in this format;
- How PIs could be encouraged as the primary resource for prescription drug information; and
- The content that is most useful for prescribers and other health care providers in the Patient Counseling Information (PCI) section of the PI.
Agenda
-
April 20
-
Welcome, Introduction, and Workshop Objectives
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityJWJanet Woodcock Director, Center for Drug Evaluation and Research - US Food and Drug Administration -
Session I: Experiences with Prescribing Information
-
Session II: Opportunities to Encourage Clinicians’ Use of Prescribing Information
-
Session III: Experiences with Patient Counseling Information and
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityRSRachel Sherman Principal, Drug and Biological Drug Products - Greenleaf Health LLCAEAmy EbelDMTDerjung Mimi Tarn David Geffen School of Medicine at UCLAJDJoan Davenport University of Maryland School of NursingSFRSandra F. Ryan Take Care Health SystemsHFHeather Free BioScrip Specialty Pharmacy -
Recap and Closing Remarks
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University
-
